Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Defining asthma control
How do patient perceptions of asthma control differ from guideline definitions?
Relvar: improved adherence vs commonly used ICS/LABAs1
A treatment is only effective if a patient takes it. When it comes to Relvar, a significantly greater proportion of patients adhere to their treatment, leading to higher persistence rates with Relvar at 12 months, vs both BUD/Form and BDP/Form.1
This graph has been independently created by GSK from the original data. The same results were first published in Parimi M, et al. Adv Ther 2020;37:2916–2931.
The percentage PDC is calculated using the formula: (number of days covered)/(total number days in period)x100, where “covered” means that the patient had a corresponding filled prescription for that day.
‘Total number of days in period’ is the number of days between index date until the patient’s censoring date (death, exit from cohort, end of study time period, or switch to another therapy), inclusive. Discontinuation is not included as a censoring criterion.
This graph has been independently created by GSK from the original data. The same results were first published in Parimi M, et al. Adv Ther 2020;37:2916–2931.
This graph has been independently created by GSK from the original data. The same results were first published in Parimi M, et al. Adv Ther 2020;37:2916–2931.
The percentage PDC is calculated using the formula: (number of days covered)/(total number days in period)×100, where “covered” means that the patient had a corresponding filled prescription for that day.
‘Total number of days in period’ is the number of days between index date until the patient’s censoring date (death, exit from cohort, end of study time period, or switch to another therapy), inclusive. Discontinuation is not included as a censoring criterion.
This graph has been independently created by GSK from the original data. The same results were first published in Parimi M, et al. Adv Ther 2020;37:2916–2931.
Patients initiating FF/VI had a 35% and 31% lower risk of discontinuing treatment compared with BUD/Form and BDP/Form respectively within 1 year after initiation (both p<0.001)1
Good adherence and quality of life
Good adherence can mean more symptom-free days and improved quality of life, with more stamina for everyday activities.2 See how else Relvar can help patients like Oscar and Paula.
Discover Relvar
Need help with this product?
Footnotes
*Percentage of patients achieving a proportion of days covered (PDC) ≥80%.
†The primary endpoint for this study was persistence measured as time to discontinuation.
FF/VI had notably less follow-up time available than comparators due to different launch dates and their consequent availability. Respective unadjusted median time to discontinuation and median follow-up time for each comparison were as follows: 99 and 393 days for FF/VI vs 116.5 and 817 days for BUD/Form; and 97 and 402 days for FF/VI vs 91 and 539 days for BDP/Form.1
Abbreviations
BDP, beclomethasone dipropionate; BUD, budesonide; CI, confidence interval; FF, fluticasone furoate; Form, formoterol; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; OR, odds ratio; PDC, percentage of days covered; VI, vilanterol.
References
- Parimi M, et al. Adv Ther 2020;37:2916–2931.
- Halterman JS, et al. J Asthma 2011;48(5):523–530.
RELVAR Ellipta was created in collaboration with
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Relvar is a registered trademark of the GlaxoSmithKline group of companies
PM-IE-FFV-WCNT-230009 June 2023
